Liquidia Analysts Boost Their Forecasts After Q4 Earnings

Core Insights - Liquidia Corp reported mixed results for Q4, with earnings of 15 cents per share, missing the analyst consensus estimate of 17 cents per share, while quarterly sales of $92.021 million exceeded the estimate of $83.634 million [1] Financial Performance - Quarterly earnings: 15 cents per share, below the consensus estimate of 17 cents per share [1] - Quarterly sales: $92.021 million, surpassing the consensus estimate of $83.634 million [1] Market Reaction - Following the earnings announcement, Liquidia shares increased by 4.5%, trading at $36.08 [2] Analyst Ratings and Price Targets - HC Wainwright & Co. analyst Andrew S. Fein maintained a Buy rating and raised the price target from $50 to $55 [4] - Wells Fargo analyst Benjamin Burnett maintained an Overweight rating and increased the price target from $31 to $44 [4] Product Adoption - CEO Dr. Roger Jeffs highlighted the rapid adoption of YUTREPIA® in clinical practice, noting it as one of the top specialty drug launches in the past five years across all therapeutic categories [2]